We are live on ! Find out more
SCLN

Sciclone Pharmaceuticals Inc
SCLN

Delisted

SCLN was delisted on the 13th of October, 2017.

116 hedge funds and large institutions have $213M invested in Sciclone Pharmaceuticals Inc in 2014 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 40 increasing their positions, 34 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 7

52% more capital invested

Capital invested by funds: $141M → $213M (+$72.9M)

22% more funds holding

Funds holding: 95116 (+21)

18% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 34

21% less call options, than puts

Call options by funds: $615K | Put options by funds: $778K

Holders
116
Holders Change
+21
Holders Change %
+22.11%
% of All Funds
3.37%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
28
Increased
40
Reduced
34
Closed
7
Calls
$615K
Puts
$778K
Net Calls
-$163K
Net Calls Change
-$409K
Name Holding Trade Value Shares
Change
Change in
Stake
Renaissance Technologies
51
Renaissance Technologies
New York
$592K -$1.41M -235,426 -73%
EMG
52
Ellington Management Group
Connecticut
$582K +$506K +84,400 New
Goldman Sachs
53
Goldman Sachs
New York
$569K +$55.8K +9,317 +13%
TA
54
Teachers Advisors
New York
$529K
AL
55
AJO LP
Pennsylvania
$528K +$459K +76,600 New
Susquehanna International Group
56
Susquehanna International Group
Pennsylvania
$497K +$132K +22,056 +44%
ACM
57
Ativo Capital Management
Illinois
$493K +$429K +71,569 New
Asset Management One
58
Asset Management One
Japan
$437K +$250K +41,762 +192%
Swiss National Bank
59
Swiss National Bank
Switzerland
$408K
BA
60
Boston Advisors
Massachusetts
$379K
SIM
61
Spark Investment Management
New York
$374K +$325K +54,300 New
RhumbLine Advisers
62
RhumbLine Advisers
Massachusetts
$357K -$2.1K -350 -0.7%
Invesco
63
Invesco
Georgia
$352K +$92.1K +15,364 +43%
NFA
64
Nationwide Fund Advisors
Ohio
$345K
ProShare Advisors
65
ProShare Advisors
Maryland
$322K -$57.3K -9,557 -17%
Wells Fargo
66
Wells Fargo
California
$313K -$28.3K -4,726 -9%
MLICM
67
Metropolitan Life Insurance Company (MetLife)
New York
$303K +$132K +22,014 +100%
Bank of America
68
Bank of America
North Carolina
$293K -$725K -120,919 -74%
Tudor Investment Corp
69
Tudor Investment Corp
Connecticut
$290K +$252K +42,053 New
FQ
70
First Quadrant
California
$286K
DIA
71
Denver Investment Advisors
Colorado
$285K -$26.8K -4,473 -10%
EGA
72
Eagle Global Advisors
Texas
$276K +$240K +40,110 New
AL
73
Airain Ltd
Guernsey
$266K +$232K +38,633 New
GMIM
74
General Motors Investment Management
New York
$261K -$96K -16,014 -30%
VOYA Investment Management
75
VOYA Investment Management
Georgia
$254K

SCLN Hedge Fund Activity: Q3 2014 in Review

116 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals Inc (SCLN) for Q3 2014, worth a combined $213M — up 52% from $141M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new SCLN positions and 7 closed out — a net gain of 21 holders — while 40 added to existing stakes and 34 trimmed.

The largest buyer was Acadian Asset Management, adding an estimated $4.56M. The largest seller was Franklin Resources, cutting an estimated $2.44M.

  • 116 institutional investors held Sciclone Pharmaceuticals Inc (SCLN) as of Q3 2014, up from 95 in Q2 2014.
  • Funds reported $213M of Sciclone Pharmaceuticals Inc stock for Q3 2014, up 52% quarter-over-quarter.
  • 28 funds opened new Sciclone Pharmaceuticals Inc positions in Q3 2014 and 7 closed out, a net change of +21 holders.
  • The largest Sciclone Pharmaceuticals Inc buyer in Q3 2014 was Acadian Asset Management, an estimated $4.56M added.
  • The largest Sciclone Pharmaceuticals Inc seller in Q3 2014 was Franklin Resources, an estimated $2.44M sold.

Based on aggregated 13F filings for Q3 2014.